Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
112.8 EUR | +0.45% | +6.11% | +4.54% |
Apr. 24 | IPSEN : Better-than-expected Q1; guidance unchanged | |
Apr. 24 | Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.54% | 9.91B | |
+25.61% | 660B | |
+23.59% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.62% | 219B | |
-9.04% | 196B | |
+6.50% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- IPN Stock
- News Ipsen
- Ipsen : Exelixis Say Phase 3 Trial of Cabozantinib Drug in Differentiated Thyroid Cancer Met Co-Primary Endpoint